scispace - formally typeset
A

Ami A. Shah

Researcher at Johns Hopkins University School of Medicine

Publications -  92
Citations -  2924

Ami A. Shah is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Scleroderma & Cancer. The author has an hindex of 26, co-authored 72 publications receiving 2120 citations.

Papers
More filters
Journal ArticleDOI

Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer

TL;DR: Analysis of peripheral blood lymphocytes and serum suggested that POLR3A mutations triggered cellular immunity and cross-reactive humoral immune responses in patients with scleroderma and provided support for the idea that acquired immunity helps to control naturally occurring cancers.
Journal ArticleDOI

Close Temporal Relationship Between Onset of Cancer and Scleroderma in Patients With RNA Polymerase I/III Antibodies

TL;DR: The findings indicate that there is a close temporal relationship between the onset of cancer and scleroderma in patients with antibodies to RNA polymerase I/III, which is distinct from sclerodma patients with other autoantibody specificities.
Journal ArticleDOI

Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma

TL;DR: There is an association with cancer among SSc patients with anti-RNAP antibodies in close temporal relationship to onset of SSc, which supports the paraneoplastic phenomenon in this subset of S sc patients.
Journal ArticleDOI

Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome.

TL;DR: The purpose of this study was to investigate whether activation of the interferon (IFN) pathway correlates with key phenotypic features in Sjögren's syndrome.
Journal ArticleDOI

Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

TL;DR: Findings support the notion that race is related to a distinct phenotypic profile in scleroderma, and a more unfavorable prognosis among African Americans, warranting heightened diagnostic evaluation and vigilant care of these patients.